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SARAbstract In the present study, novel derivatives of 4H-benzo[h]chromene and 7H-benzo[h]
chromeno[2,3-d]pyrimidine were prepared and evaluated for their anti-proliferative activity against
three human tumor cell lines breast adenocarcinoma (MCF-7), human colon carcinoma (HCT-116)
and hepatocellular carcinoma (HepG-2) in comparison with the standard drugs Doxorubicin, Vin-
blastine and Colchicine using MTT colorimetric assay. The structures of the target compounds were
established on the basis of spectral data. We explored the Structure–Activity Relationship (SAR) of
4H-benzo[h]chromenes with modification at the 2- or 3- and 2, 3-positions. It was found that several
compounds showed good antitumor activity against the cell lines MCF-7, HCT-116 and HepG-2 as
compared to the standard drugs. The SAR study revealed that the antitumor activity of the synthe-
sized compounds was significantly affected by the lipophilicity (hydrophobic or hydrophilic) of the
substituent at 2- or 3- and 2, 3-positions.
 2016 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The considerable biological and medicinal activities of fused
4H-chromene has stimulated much research in this field. More-
over, functionally substituted chromenes have played increas-
ing roles in synthetic approaches to promising compounds in
the field of medicinal chemistry including antimicrobial
[26,35,15,22], antiproliferative and apoptosis inducing [25,36],
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cicidal [1,2]), antitumor [10,20,29,32,3,7], leishmanicidal
[31,4], anticonvulsant [11], antioxidant [24,33,12], effects and
activities, as well as treatment of Alzheimer’s disease [5] and
Schizophrenia disorder [16]. They also exhibit blood platelet
antiaggregating [19], analgesic ([9]), hypolipidemic [30],
vascular-disrupting activity [14], estrogenic anticoagulant and
antispasmolytic [24], DNA breaking activities and mutagenic-
ity activities [13]. With these in mind, we decided to synthesize
new oligo substituted 4H-benzo[h]chromenes bearing a 4-aryl
group at the 4-position and a pyrimidine moieties at the 2, 3-
position as potential cytotoxic agents against a variety of
human cancer cell lines. The Structural–Activity Relationship
(SAR) of the 2- or 3- and 2, 3-positions are also discussed.
2. Experimental
2.1. Instruments
Melting points measured with a Stuart Scientific Co. Ltd appa-
ratus are uncorrected. IR spectra were recorded using KBr
disk on a Jasco FT/IR 460 plus spectrophotometer. The 1H
NMR and 13C NMR spectra were measured on BRUKER
AV 500 MHz spectrometer in DMSO-d6 as solvent, using
tetramethylsilane (TMS) as an internal standard, and chemical
shifts are expressed as d (ppm). 13C NMR spectra were
obtained using distortionless enhancement by polarization
transfer (DEPT), where the signals of CH and CH3 carbon
atoms appear normal (up), the signals of carbon atoms in
CH2 environments appear negative (down) or attached proton
test (APT), with this technique, the signals of CH and CH3 car-
bon atoms appear normal (up) and the signal of CH2 and Cq
environments appears negative (down). The Microwave appa-
ratus used is Milestone Sr1, Microsynth. Mass spectra were
determined on a Shimadzu GC/MS-QP5050A spectrometer.
Elemental analyses were performed on a Perkin–Elmer 240
microanalyser.
2.2. Procedure
2.2.1. 2-Amino-4-(4-bromophenyl)-6-methoxy-4H-benzo[h]
chromene-3-carbonitrile (1)
The compound 1 was prepared as per procedure reported in
[6].
2.2.2. Ethyl 2-amino-4-(4-bromophenyl)-6-methoxy-4H-benzo
[h]chromene-3-carboxyalte (2)
The compound 2 was prepared as per procedure reported in
[6].
2.2.3. General procedure for the preparation of (7a,b)
A solution of 2-amino-4-(4-bromophenyl)-6-methoxy-4H-
benzo[h]chromene-3-carbonitrile 1 (0.01 mol) in acetic anhy-
dride (20 mL) was refluxed for ½ or 6 h. The solvent was
removed under reduced pressure and the resulting solid was
collected and washed with cooled ethanol, filtered, dried and
recrystallized from ethanol to afford 7a,b. The physical and
spectral data of compounds 7a,b are as follows:2.2.3.1. 2-Acetylamino-4-(4-bromophenyl)-6-methoxy-4H-
benzo[h]chromene-3-carbonitrile (7a). Yellow powder; m.p.
162–163 C; yield 73%; IR (KBr) t (cm1): 3214 (NH), 3077,
2992, 2934 (CH stretching), 2221 (CN), 1740 (CO); 1H NMR
d: 10.75 (s, 1H, NH), 8.15–6.60 (m, 9H, aromatic), 5.19 (s,
1H, H-4), 3.85 (s, 3H, OCH3), 2.14 (s, 3H, COCH3);
13C
NMR d: 170.63 (CO), 168.47 (C-2), 152.65 (C-6), 137.10 (C-
10b), 129.75 (C-10a), 127.99 (C-9), 126.61 (C-8), 124.68 (C-
6a), 123.65 (C-7), 121.74 (C-10), 120.80 (C-4a), 117.01 (CN),
102.86 (C-5), 91.54 (C-3), 55.93 (CH3), 41.99 (C-4), 23.10
(CH3), 141.55, 132.00, 131.82, 120.57 (aromatic); MS m/z
(%):450 (M++2, 30.26), 448 (M+, 32.04) with a base peak
at 251 (100); Anal. Calcd for C23H17BrN2O3: C, 61.48; H,
3.81; N, 6.23. Found: C, 61.52; H, 3.79; N, 6.38%
2.2.3.2. 2-Diacetylamino-4-(4-bromophenyl)-6-methoxy-4H-
benzo[h]chromene-3-carbonitrile (7b). Colorless powder; m.
p. 168–169 C; yield 95%; IR (KBr) t (cm1): 3060, 2982,
2935, 2882, 2830 (CH stretching), 2221 (CN), 1741 (CO); 1H
NMR d: 8.15–6.55 (m, 9H, aromatic), 5.41(s, 1H, H-4), 3.85
(s, 3H, OCH3), 2.51 (s, 6H, 2COCH3);
13C NMR d: 170.58
(CO), 152.65 (C-2), 152.15 (C-6), 137.10 (C-10b), 129.97 (C-
10a), 127.99 (C-9), 126.90 (C-6a), 124.68 (C-8), 123.51 (C-7),
121.74 (C-10), 121.30 (C-4a), 115.55 (CN), 102.74 (C-5),
91.54 (C-3), 55.93 (CH3), 42.00 (C-4), 25.01 (CH3), 141.55,
132.00, 130.46, 120.64 (aromatic); MS m/z (%): 492 (M++2,
20.08), 490 (M+, 22.09) with a base peak at 252 (100); Anal.
Calcd for C25H19BrN2O4: C, 61.11; H, 3.90; N, 5.70. Found:
C, 61.22; H, 3.79; N, 5.87%.
2.2.4. 2-Benzylideneamino-4-(4-bromophenyl)-6-methoxy-4H-
benzo[h]chromene-3-carbonitrile (8)
Amixture of compound 1 (0.01 mol), benzaldehyde (0.01 mol),
piperidine (0.5 mL) in ethanol (20 mL) was refluxed for 2 h.
The solid product which formed was filtered, washed with
cooled methanol, dried and recrystallised from ethanol to
afforded 8 as yellow needles; m.p. 241–242 C; yield 79%;
IR (KBr) t (cm1): 3068, 3017, 2958, 2917, 2878 (CH stretch-
ing), 2210 (CN); 1H NMR d: 9.23 (s, 1H, N‚CH), 8.52–6.53
(m, 14H, aromatic), 5.33 (s, 1H, H-4), 3.85 (s, 3H, OCH3);
13C
NMR d: 163.79 (N‚CH), 157.91 (C-2), 152.00 (C-6), 136.90
(C-10b), 127.73 (C-10a), 126.73, (C-9), 124.78 (C-8), 124.03
(C-6a), 121.66 (C-7), 121.28 (C-10), 120.91 (C-4a), 115.73
(CN), 102.99 (C-5), 86.59 (C-3), 55.84 (CH3), 42.35 (C-4),
142.66, 134.75, 133.51, 131.90, 130.46, 130.11, 129.12, 117.52
(aromatic); MS m/z (%): 496 (M++2, 16.32), 494 (M+,
16.83) with a base peak at 340 (100); Anal. Calcd for
C28H19BrN2O2: C, 67.89; H, 3.87; N, 5.66. Found: C, 67.90;
H, 3.91; N, 5.76%.
2.2.5. 4-(4-Bromophenyl)-2-ethoxymethyleneamino-6-methoxy-
4H-benzo[h]chromene-3-carbonitrile (10)
A mixture of 1 (0.01 mol) with triethyl orthoformate
(0.01 mol) and acetic anhydride (30 mL) was refluxed for 2 h.
The solvent was removed under reduced pressure and the
resulting solid was washed with methanol and recrystallized
from benzene to give 10 as yellow needles; m.p. 197–198 C;
yield 74%; IR (KBr) t (cm1): 3068, 2975, 2932, 2840 (CH
stretching), 2209 (CN); 1H NMR d: 8.61 (s, 1H, N‚CH),
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CH2, J= 7.2 Hz), 3.87 (s, 3H, OCH3), 1.44 (t, 3H, CH3,
J= 7.2 Hz); 13C NMR d: 159.55 (N‚CH), 157.54 (C-2),
152.91 (C-6), 138.10 (C-10b), 127.70 (C-10a), 126.64 (C-9),
125.88(C-6a), 124.70 (C-8), 122.60 (C-7), 121.92 (C-10),
120.68 (C-4a), 115.44(CN), 102.81 (C-5), 80.57 (C-3), 64.53
(CH2), 55.95 (CH3), 43.65 (C-4), 14.16 (CH3), 142.54, 132.32,
130.26, 118.35 (aromatic); MS m/z (%): 464 (M++2, 14.97),
462 (M+, 15.04) with a base peak at 308 (100); Anal. Calcd
for C24H19BrN2O3: C, 62.22; H, 4.13; N, 6.05. Found: C,
62.25; H, 4.21; N, 6.12%.
2.2.6. 4-(4-Bromophenyl)-2-dimethylaminomethyleneamino-6-
methoxy-4H-benzo[h]chromene-3-carbonitrile (11)
Method (a): Amixture of 1 (0.01 mol) with dimethylformamide-
dipentylacetal (DMF-DPA) (0.01 mol) and benzene (30 mL)
was refluxed for 3 h. The solvent was removed under
reduced pressure and the resulting solid was recrystallized
from benzene to give 11 as colorless needles; m.p. 248–249
C; yield 72%; IR (KBr) t (cm1): 3060, 2958, 2916, 2797
(CH stretching), 2196 (CN); 1H NMR d: 8.11 (s, 1H, N‚CH),
7.70–6.51 (m, 9H, aromatic), 5.00 (s, 1H, H-4), 3.82 (s, 3H,
OCH3), 3.26, 3.06 (s, 6H, 2CH3);
13C NMR d: 159.60
(N‚CH), 154.45 (C-2), 151.17 (C-6), 137.24 (C-10b), 127.22
(C-10a), 126.22 (C-9), 124.44 (C-6a), 123.89 (C-8), 121.40
(C-7), 120.48 (C-10), 120.05 (C-4a), 116.38(CN), 103.13
(C-5), 71.44 (C-3), 55.60 (CH3), 42.03 (C-4), 34.16 (CH3),
144.21, 131.50, 129.85, 121.20 (aromatic); MS m/z (%): 463
(M++2, 14.35), 461 (M+, 13.66) with a base peak at 307
(100); Anal. Calcd for C24H20BrN3O2: C, 62.35; H, 4.36; N,
9.09. Found: C, 62.40; H, 4.41; N, 9.13%.
Method (b): A mixture of imadate 10 (0.01 mol) and
dimethylamine in methanol (30 mL), was stirred for 1 h. and
the mixture was left overnight. The solid product was collected
by filtration, washed with methanol and recrystallized from
proper solvent to afford 11 (m.p., mixed m.p., identical IR
and MS spectrum).
2.2.7. 2-Aminomethyleneamino-4-(4-bromophenyl)-6-methoxy-
4H-benzo[h]chromene-3-carbonitrile (12)
Compound 12 was prepared from imadate 10 (0.01 mol) and
NH3 gas in methanol (30 mL) according to the procedure
described for 11 (Method b) to afford 12 as colorless needles
from ethanol; m.p 240–241 C; yield 76%; IR (KBr) t
(cm1): 3444, 3346, 3163 (NH2), 3012, 2954, 2934, 2870 (CH
stretching), 2203 (CN); 1H NMR d: 8.62–6.52 (m, 9H, aro-
matic), 8.27 (s, 1H, N‚CH), 7.38 (s, 2H, NH2), 5.01 (s, 1H,
H-4), 3.82 (s, 3H, OCH3);
13C NMR d: 160.53 (C-2), 155.01
(N‚CH), 151.32 (C-6), 137.26 (C-10b), 127.39 (C-9), 126.34
(C-8), 124.57 (C-10a), 123.98 (C-6a), 121.67 (C-7), 120.74 (C-
10), 120.24 (C-4a), 116.57 (CN), 103.25 (C-5), 71.72 (C-3),
55.75 (CH3), 42.17 (C-4), 144.24, 131.64, 130.03, 120.08 (aro-
matic); 13C NMR-DEPT spectrum at 135o CH, CH3 signals
are positive (up), CH2 signals are negative (down), revealed
the following signals at d: 155.01 (N‚CH "), 131.64 (aromatic
"), 130.03 (aromatic "), 127.39 (C-9 "), 126.34 (C-8 "), 121.67
(C-7 "), 120.74 (C-10 "), 103.25 (C-5 "), 55.75 (CH3 "), 42.17
(C-4 "), 131.64 (aromatic "), 130.03 (aromatic "). In the DEPT
spectrum at 90 only CH signals are positive (up) and showed
d: 155.01 (N‚CH "), 131.64 (aromatic "), 130.03 (aromatic "),127.39 (C-9 "), 126.34 (C-8 "), 121.67 (C-7 "), 120.74 (C-10 "),
103.25 (C-5 "), 42.17 (C-4 "), 131.64 (aromatic "), 130.03 (aro-
matic "). In the DEPT spectrum at 45 (CH, CH2 and CH3
positive) revealed signals at d: 155.01 (N‚CH "), 131.64 (aro-
matic "), 130.03 (aromatic "), 127.39 (C-9 "), 126.34 (C-8 "),
121.67 (C-7 "), 120.74 (C-10 "), 103.25 (C-5 "), 55.75 (CH3
"), 42.17 (C-4 "), 131.64 (aromatic "), 130.03 (aromatic ");
13CNMR-APT spectrum CH, CH3 positive (up), CH2, Cq neg-
ative (down), revealed the following signals at d: 160.53 (C-2
;), 155.01 (N‚CH ;), 151.32 (C-6 ;), 144.24 (aromatic ;),
137.26 (C-10b ;), 131.64 (aromatic "), 130.03 (aromatic "),
127.39 (C-9 "), 126.34 (C-8 "), 124.57 (C-10a ;), 123.98 (C-
6a ;), 121.67 (C-7 "), 120.74 (C-10 "), 120.24 (C-4a ;),
120.08 (aromatic ;), 116.57 (CN ;), 103.25 (C-5 "), 71.72 (C-
3 ;), 55.75 (CH3 "), 42.17 (C-4 "); MS m/z (%): 435
(M++2, 3.11), 433 (M+, 3.26) with a base peak at 77 (100);
Anal. Calcd for C22H16BrN3O2: C, 60.84; H, 3.71; N, 9.68.
Found: C, 60.79; H, 3.68; N, 9.63%.
2.2.8. Ethyl 4-(4-bromophenyl)-2-formamido-6-methoxy-4H-
benzo[h]chromene-3-carboxylate (14)
Compound 14 was prepared from 2 (0.01 mol), triethyl ortho-
formate (0.01 mol) and acetic anhydride (30 mL) according to
the procedure described for 10. Compound 14 was recrystal-
lized from benzene as colorless powder; m.p. 175–176 C; yield
63%; IR (KBr) t (cm1): 3417 (NH), 3052, 3009, 2978, 2905
(CH stretching), 1729 (CO), 1677 (CO); 1H NMR d: 10.80
(bs, 1H, NH), 10.64 (s, 1H, CHO), 8.24–6.82 (m, 9H,
aromatic), 5.16 (s, 1H, H-4), 4.08 (q, 2H, CH2, J= 7.2 Hz),
3.87 (s, 3H, OCH3), 1.17 (t, 3H, CH3, J= 7.2 Hz);
13C
NMR d: 168.09 (CO), 166.41 (CO), 152.08 (C-2), 151.94
(C-6), 137.11 (C-10b), 129.53 (C-10a), 128.29 (C-9), 127.37
(C-6a), 126.18 (C-8), 124.24 (C-7), 123.59 (C-10), 121.59
(C-4a), 103.36 (C-5), 92.04 (C-3), 60.10 (CH2), 55.85 (CH3),
40.16 (C-4), 13.95 (CH3), 144.90, 131.74, 129.52, 120.93 (aro-
matic); MS m/z (%): 483 (M++2, 17.19), 481 (M+, 18.15)
with a base peak at 68 (100); Anal. Calcd for C24H20BrNO5:
C, 59.76; H, 4.18; N, 2.90. Found: C, 59.79; H, 4.20; N, 2.94%.2.2.9. Ethyl 2-dimethylaminomethyleneamino-4-(4-bromophenyl)-
6-methoxy-4H-benzo[h]chromene-3-carboxylate (15)
Compound 15 was prepared from 2 (0.01 mol), dimethylfor
mamide-dipentylacetal (DMF-DPA) (0.01 mol) and benzene
(30 mL) according to the procedure described for 11 (Method
a) to give 15 as pale yellow crystals from benzene; m.p. 182–
183 C; yield 67%; IR (KBr) t (cm1): 3041, 2970, 2888 (CH
stretching), 1687 (CO); 1H NMR d: 8.25 (s, 1H, N‚CH),
8.23–6.79 (m, 9H, aromatic), 5.15 (s, 1H, H-4), 4.00 (q,
2H, CH2, J= 7.2 Hz), 3.88 (s, 3H, OCH3), 3.18, 3.08 (s,
6H, 2CH3), 1.15 (t, 3H, CH3, J= 7.2 Hz);
13C NMR d:
166.77 (CO), 160.79 (N‚CH), 155.66 (C-2), 150.84 (C-6),
137.70 (C-10b), 128.02 (C-10a), 126.78 (C-9), 125.49 (C-6a),
123.92 (C-8), 123.67 (C-7), 121.31 (C-10), 120.66 (C-4a),
103.33 (C-5), 88.92 (C-3), 58.66 (CH2), 55.48 (CH3), 42.17
(C-4), 34.03 (CH3), 13.88 (CH3), 146.33, 130.58, 129.32,
119.65 (aromatic); MS m/z (%): 510 (M++2, 10.04), 508
(M+, 11.25) with a base peak at 208 (100); Anal. Calcd
for C26H25BrN2O4: C, 61.30; H, 4.95; N, 5.50. Found: C,
61.27; H, 5.00; N, 5.58%.
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chromeno[2,3-d]pyrimidin-8-one (16)
A mixture of compound 1 (0.01 mol) and formic acid (30 mL)
was refluxed for 3–5 h. (TLC monitoring). The excess of for-
mic acid was removed under reduced pressure and the resulting
solid was recrystallised from ethanol/benzene to gave 16 as
pale yellow crystals; m.p. 170–171 C; yield 74%; IR (KBr) t
(cm1): 3500 (NH), 3067, 3001, 2958, 2932, 2891, 2836 (CH
stretching), 1763 (CO); 1H NMR d: 8.21–6.07 (m, 10H, aro-
matic, H-10), 8.11 (bs, 1H, NH), 5.03 (s, 1H, H-7), 3.93 (s,
3H, OCH3);
13C NMR d: 161.74 (CO), 161.33 (C-11a),
152.11 (C-5), 151.56 (C-10), 138.92 (C-1b), 130.00 (C-1a),
128.00 (C-4a), 126.82 (C-2), 124.93 (C-3), 123.52 (C-4),
121.86 (C-1), 121.73 (C-6a), 118.81 (C-6), 114.91 (C-7a),
56.02 (CH3), 42.83 (C-7), 139.01, 136.44, 132.10, 120.36 (aro-
matic); MS m/z (%): 436 (M++2, 40.32), 434 (M+, 40.45)
with a base peak at 67 (100); Anal. Calcd for C22H15BrN2O3:
C, 60.71; H, 3.47; N, 6.44. Found: C, 60.82; H, 3.58; N, 6.53%.
2.2.11. 8-Amino-7-(4-bromophenyl)-5-methoxy-7H-benzo[h]
chromeno[2,3-d]pyrimidine (17)
A mixture of 12 (0.01 mol) in ethanol (30 ml) and piperidine
(0.5 mL) was heat under reflux for 2 h. The solid product
which formed was collected by filtration, washed with metha-
nol and recrystallized from ethanol to give 17 as colorless nee-
dles; m.p. 273–274 C; yield 91%; IR (KBr) t (cm1): 3482,
3422, 3305 (NH2), 3096, 3005, 2916, 2895 (CH stretching);
1H NMR d: 8.27–6.59 (m, 9H, aromatic), 8.18 (s, 1H, H-10),
6.90 (s, 2H, NH2), 5.38 (s, 1H, H-7), 3.90 (s, 3H, OCH3);
13C NMR d: 162.66 (C-8), 162.34 (C-11a), 156.68 (C-10),
151.42 (C-5), 137.75 (C-1b), 127.52 (C-1a), 126.36 (C-2),
124.52 (C-4a), 124.19 (C-3), 121.69 (C-4), 120.73 (C-1),
118.60 (C-6a), 103.16 (C-6), 95.20 (C-7a), 55.81 (CH3), 38.26
(C-7), 143.34, 131.53, 129.83, 120.14 (aromatic); MS m/z
(%): 435 (M++2, 82.19), 433 (M+, 83.00) with a base peak
at 68 (100); Anal. Calcd for C22H16BrN3O2: C, 60.84; H,
3.71; N, 9.68. Found: C, 60.90; H, 3.80; N, 9.71%.
2.2.12. 7-(4-Bromophenyl)-5-methoxy-8-imino-9-methyl-7H-
benzo[h]chromeno[2,3-d]pyrimidine (18)
Compound 18 was prepared from imadate 10 (0.01 mol) and
methylamine in methanol (30 mL) according to the procedure
described for 11 (Method b) to afford 18 as colorless crystals
from ethanol/benzene; m.p. 241–242 C; yield 81%; IR
(KBr) t (cm1): 3333 (NH), 3060, 3009, 2954, 2899, 2822
(CH stretching); 1H NMR d: 8.21–6.64 (m, 9H, aromatic),
8.18 (s, 1H, H-10), 6.55 (bs, 1H, NH2), 5.31 (s, 1H, H-4),
3.86 (s, 3H, OCH3), 3.34 (s, 3H, CH3);
13C NMR (125 MHz,
CDCl3) d (ppm): 159.00 (C-8), 156.74 (C-11a), 151.39 (C-10),
143.77 (C-10, aromatic C-1), 137.16 (C-1b), 127.43 (C-2),
126.27 (C-3), 124. 43 (C-1a), 124.00 (C-4a), 121.65 (C-4),
120.71 (C-1), 120.09 (C-6a), 103.40 (C-6), 97.30 (C-7a), 55.73
(CH3), 40.11 (C-4), 35.26 (CH3), 131.59, 129.94, 117.85 (aro-
matic); MS m/z (%): 449 (M++2, 68.9), 447 (M+, 70.8) with
a base peak at 75 (100); Anal. Calcd for C23H18BrN3O2: C,
61.62; H, 4.05; N, 9.37. Found: C, 61.66; H, 4.10; N, 9.41%.
2.2.13. 9-Amine-7-(4-bromophenyl)-5-methoxy-8-imino-7H-
benzo[h]chromeno[2,3-d]pyrimidine (19)
A mixture of imadate 10 (0.01 mol) and hydrazine hydrate
(0.01 mol) in ethanol (30 mL) was stirred at room temperaturefor 1 h. The solid product was collected by filtration, washed
with methanol and recrystallised from benzene to give 19 as
colorless powder from benzene; m.p. 221–222 C; yield 73%;
IR (KBr) t (cm1): 3331, 3271, 3196, 3162 (NH and NH2),
3068, 3001, 2950 (CH stretching); 1H NMR d: 8.22–6.69 (m,
9H, aromatic), 8.30 (s, 1H, H-10), 7.46 (bs, 1H, NH), 6.69
(bs, 2H, NH2), 5.33 (s, 1H, H-7), 3.87 (s, 3H, OCH3);
13C
NMR d: 155.00 (C-8), 152.00 (C-11a), 151.45 (C-5), 137.00
(C-10), 131.38 (C-1b), 127.42 (C-1a), 126.25 (C-2), 124.43
(C-4a), 124.01 (C-3), 121.67 (C-4), 120.68 (C-1), 118.00 (C-6a),
103.00 (C-6), 98.50 (C-7a), 55.77 (CH3), 40.05 (C-7), 144.00,
130.18, 128.30, 121.50 (aromatic); MS m/z (%):450 (M++2,
10.85), 448 (M+, 12.67) with a base peak at 435 (100); Anal.
Calcd for C22H17BrN4O2: C, 58.81; H, 3.81; N, 12.47. Found:
C, 58.84; H, 3.88; N, 12.63%.
2.2.14. 9-Benzylideneamino-7-(4-bromophenyl)-5-methoxy-8-
imino-7H-benzo[h]chromeno[2,3-d]pyrimidine (20)
A mixture of imino compound 19 (0.01 mol) and benzaldehyde
(0.01 mol) in ethanol (30 mL) and piperidine (0.5 mL) was
refluxed for 2 h. The solvent was removed under reduced pres-
sure and the resulting solid was recrystallized from benzene to
give the open chain product 20 as pale yellow crystals from
ethanol/benzene; m.p. 274–275 C; yield 89%; IR (KBr) t
(cm1): 3216 (NH), 3040, 2937 (CH stretching), 1650
(C‚N); 1H NMR d: 11.06 (bs, 1H, NH), 8.44 (N‚CH),
8.22 (s, 1H, H-10), 8.28–6.81 (m, 14H, aromatic), 6.17 (s,
1H, H-7), 3.97 (s, 3H, OCH3);
13C NMR d: 163.87 (C-8),
158.45 (C-10), 156.57 (N‚CH), 151.68 (C-11a), 144.54 (C-5),
137.59 (C-1b), 127.55 (C-1a), 126.77 (C-2), 126.35 (C-4a),
124.53 (C-3), 124.03 (C-4), 121.73 (C-1), 118.80 (C-6a), 103.37
(C-6), 96.77 (C-7a), 55.99 (CH3), 38.54 (C-7), 143.88, 134.23,
131.64, 129.62, 129.44, 128.91, 128.50, 120.57 (aromatic); 538
(M++2, 4.61), 536 (M+, 4.70) with a base peak at 433 (100);
Anal. Calcd for C29H21BrN4O2: C, 64.81; H, 3.94; N, 10.43.
Found: C, 64.77; H, 3.99; N, 10.48%.2.3. Antitumor screening
2.3.1. Cell culture and cytotoxicity evaluation using viability
assay
Compounds 7, 8, 10–12 and 14–20 were initially evaluated for
in vitro antitumor activity against three different human cell
lines: MCF-7, HCT-116 and HepG-2 in comparison with
Doxorubicin, Vinblastine and Colchicine. The measurements
of cell growth and the viabilities and in vitro cytotoxicity eval-
uation using viability assay were determined as described in the
literature [23,27] and the result is cited in Table 1 and Fig. 1.3. Results and discussion
3.1. Chemistry
The synthetic pathways for synthesis of key intermediates 2-
amino-4-(4-bromophenyl)-6-methoxy-4H-benzo[h]chromene-
3-carbonitrile 1 and ethyl 2-amino-4-(4-bromophenyl)-6-meth
oxy-4H-benzo[h]chromene-3-carboxylate 2 are outlined in
(Scheme 1). One-pot three component condensation of the
4-methoxy-1-naphthol 3, 4-bromobenzaldehyde 4 and malonon-
itrile 5 or ethyl cyanoacetate 6 in ethanolic piperidine solution
Table 1 SAR of 2-, 3- or 2, 3-positions and cytotoxic activity (IC50 lg/ml) of 4H-chromene and 7H-chromenopyrimidine derivatives
against different cell lines in comparison with Doxorubicin, Vinblastine and Colchicine as measured with the MTT method.a
O R
CN
Ar
MeO
1,7,8,10-12 2,14,15
O R
CO2Et
Ar
MeO
16
17
O N
Ar
NH
O
MeO
O N
Ar
N
NH2
MeO
18-20
O N
Ar
N
NH
MeO R
Cpd. R MCF-7 HCT-116 HepG-2 Cpd. R MCF-7 HCT-116 HepG-2
1 NH2 17.7 ± 0.18 3.7 ± 0.11 5.9 ± 0.2 15 N‚CHNMe2 w w w
2 NH2 6.5 ± 0.3 4.1 ± 0.12 29.8 ± 0.036 16 – 6.0 ± 0.24 2.7 ± 0.35 7.9 ± 0.08
7a NHAc 5.1 ± 0.02 10.6 ± 0.21 3.1 ± 0.4 17 – 8.9 ± 0.11 23.9 ± 0.08 1.6 ± 0.9
7b NAc2 0.7 ± 0.3 0.56 ± 0.14 0.37 ± 0.06 18 Me w w 9.6 ± 0.07
8 N‚CHPh 24.7 ± 0.04 26.1 ± 0.05 22.2 ± 0.09 19 NH2 0.24 ± 0.21 0.32 ± 0.028 5.1 ± 0.3
10 N‚CHOEt w w w 20 N‚CHPh 41.5 ± 0.01 7.4 ± 0.08 28.2 ± 0.08
11 N‚CHNMe2 w w w Doxorubicin – 0. 43 ± 0.11 0.47 ± 0.02 0.9 ± 0.4
12 N‚CHNH2 0.9 ± 0.05 1.0 ± 0.011 12.1 ± 0.08 Vinblastine – 6.1 ± 0.03 2.6 ± 0.08 4.6 ± 0.01
14 NHCHO 22.1 ± 0.2 21.9 ± 0.1 33.2 ± 0.2 Colchicine – 17.7 ± 0.01 42.8 ± 0.02 10.6 ± 0.04
w = weak activity (IC50 > 50 lg/ml).
a IC50 values expressed in lg/ml as the mean values of triplicate wells from at least three experiments and are reported as the mean ± standard
error.
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Figure 1 IC50 values expressed in lg/ml of 4H-chromene and 7H-chromenopyrimidine derivatives against MCF-7, HCT-116 and HepG-
2 tumor cells.
86 A.M. El-Agrody et al.under Microwave irradiation conditions for 2 min. at 140 C
afforded the target compounds 1 and 2 respectively,
(Scheme 1). The maximum power of Microwave irradiation
was optimized by repeating the reaction at different watt pow-
ers and time. Microwave radiations at 400 W and reaction time
2 min. gave the highest yield.
Acylation of 2-amino-4-(4-bromophenyl)-6-methoxy-4H-
benzo[h]chromene-3-carbonitrile 1 with acetic anhydride underreflux for ½ h. afforded the corresponding the N-acetyl deriva-
tive, 2-acetylamino-4-(4-bromophenyl)-6-methoxy-4H-benzo
[h]chromene-3-carbonitrile 7a, while acylation of 1 with acetic
anhydride under reflux for 6 h. afforded the corresponding N,
N-diacetyl derivative, 2-diacetylamino-4-(4-bromophenyl)-6-
methoxy-4H-benzo[h]chromene-3-carbonitrile 7b (Scheme 2).
Condensation of 1 with benzaldehyde in the ethanolic piperi-
dine solution under reflux afforded 2-benzylideneamino-4-(4-
OH
3 OMe
1
5
4a 34
27
8
6
O NH2
CN
Ar
6a
9
10
a
b
cdef
g
h
1
MeO
10a
2
O NH2
CO2Et
Ar
MeO
10b
MW / 400 W / 2 min.MW / 400 W / 2 min.
Ar = p-BrC6H4
EtOH / pip.
ArCHO (4) / CH2(CN)2 (5)ArCHO (4) / CNCH2CO2Et (6)
EtOH / pip.
Scheme 1 Synthesis of 4H-benzo[h]chromene dericatives (1, 2).
O NH2
CN
Ar
O N
Ar
N
Ph
NH
NH2
MeO
MeO
O N=CHPh
CN
Ar
MeO
18
9
NH2NH2.H2O
O
CN
NR
Ar
MeO
7a,b
or
a; R = HAc
b; R = Ac2
Ac2O / 1/2
6 h. reflux
Ar = p-BrC6H4
reflux
EtOH / pip.
1
PhCHO
O N=CHOEt
CN
Ar
MeO
10
HC(OEt)3
Ac2O
O
CN
Ar
N=CHNMe2
MeO
11
DMF-DPA
stirring
reflux
reflux
benzene
O N=CHNH2
CN
Ar
MeO stirring
NH3 gas Me2NH
12
Scheme 2 Synthetic protocol of 2-substituted 4-(4-bromophenyl)-6-methoxy-4H-benzo[h]chromene-3-carbonitriles (7, 8, 10–12).
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8. When compound 8 was treated with hydrazine hydrate in
ethanol at room temperature or under reflux, it afforded the
b-enaminonitrile 1 (m.p., mixed m.p., identical IR and MS
spectrum) rather than the pyrimidine derivative 9 [17]
(Scheme 2). Reaction of compound 1 with triethyl orthofor-
mate in acetic anhydride under reflux gave the corresponding
4-(4-bromophenyl)-2-ethoxymethyleneamino-6-methoxy-4H-
benzo[h]chromene-3-carbonitrile 10, while condensation of 1
with dimethylformamide-dipentylacetal (DMF-DPA) in ben-
zene under reflux gives the 4-(4-bromophenyl)-2-dimethylami
nomethyleneamino-6-methoxy-4H-benzo[h]chromene-3-carbo-
nitrile 11 respectively, (Scheme 2). Interaction of the imidate 10
with dimethylamine in methanol at room temperature under
stirring for 1 h. yielded the imidine 11, which can be obtained
as described before from the reaction of 1 and DMF-DPA (m.
p., mixed m.p., identical IR and MS spectrum), while
ammonolysis of 10 with NH3 gas bubbled in methanol at room
temperature under stirring for 1 h. giving the open chain pro-
duct 2-aminomethyleneamino-4-(4-bromophenyl)-6-methoxy-
4H-benzo[h]chromene-3-carbonitrile 12 (Scheme 2).
Similarly, the reaction of b-enaminoester 2 with triethyl
orthoformate afforded ethyl 4-(4-bromophenyl)-2-formamido-
6-methoxy-4H-benzo[h]chromene-3-carboxylate 14, instead of
the corresponding ethyl 2-ethoxymethyleneamino-4-(4-bromo
phenyl)-6-methoxy-4H-benzo[h]chromene-3-carboxylate 13,
while reaction of 2 with dimethylformamide-dipentylacetal
(DMF-DPA) gave ethyl 2-dimethylaminomethyleneamino-4-
(4-bromophenyl)-6-methoxy-4H-benzo[h]chromene-3-carboxy-
late 15 (Scheme 3). The formation of compound 14 can be
rationalized through the initial product of addition of H2Oto ethoxymethyleneamino group (–N‚CHOEt) of 13, which
loses ethanol to give 2-formamido derivatives 14 [8]. These
results are depicted in (Scheme 3).
The b-enaminonitrile 1 and the imidate 10 proved to be a
useful intermediate for the synthesis of a variety of pyrimidine
derivatives. Thus, condensation of 1 with formic acid under
reflux gave 7-(4-bromophenyl)-5-methoxy-7H,9H-benzo[h]
chromeno[2,3-d]pyrimidin-8-one 16, while reaction of 1 with
formamide under reflux was unsuccessful, the 8-amino-7-(4-b
romophenyl)-5-methoxy-7H-benzo[h]chromeno[2,3-d]pyrim-
idine 17 was not formed. Compound 17 can be prepared by
cyclization of 12 in ethanolic piperidine solution under reflux
[17]. These results are depicted in (Scheme 4).
Treatment of the imidate 10 with methylamine in methanol
at room temperature under stirring for 1 h. gave the cycloaddi-
tion product 7-(4-bromophenyl)-5-methoxy-8-imino-9-methyl-
7H-benzo[h]chromeno[2,3-d]pyrimidine 18, while hydrazinoly-
sis of 10 afforded the corresponding cycloaddition product
9-amine-7-(4-bromophenyl)-5-methoxy-8-imino-7H-benzo[h]
chromeno[2,3-d] pyrimidine 19 (Scheme 5). In addition,
condensation of the aminoimino derivative 19 with
benzaldehyde in ethanolic piperidine solution under
reflux gave the open chain product 9-benzylideneamino-7-
(4-bromophenyl)-5-methoxy-8-imino-7H-benzo[h]chromeno
[2,3-d]pyrimidine 20. These results are depicted in
(Scheme 5).
The structures 7, 8, 10–12 and 14–20 were established on
the basis of IR, 1H NMR, 13C NMR and MS data. The 4-
position of compounds 7, 8, 10–12, 14, 15 and the 7-position
of compounds 16–20 is chiral center and all the reactions were
controlled using TLC technique.
O NH2
CO2Et
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MeO
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CO2Et
NHCHO
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MeO
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O N=CHNMe2
CO2Et
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MeO
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O
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Ar = p-BrC6H4
HC(OEt)3
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Scheme 3 Synthetic protocol of ethyl 2-formamid o/dimethylamiomethyleneamino derivatives (13, 14).
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Scheme 4 Synthetic protocol of the pyrimidine derivatives (16, 17).
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Scheme 5 Synthetic protocol of compounds (18–20).
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Anti-proliferative activity of the newly synthesized compounds
7, 8, 10–12 and 14–20 were examined in three human cancer
cell lines, namely, breast adenocarcinoma (MCF-7), human
colon carcinoma (HCT-116) and hepatocellular carcinoma
(HepG-2) using MTT colorimetric assay as described in the lit-
erature [23,27]. In-vitro cytotoxicity evaluation using viability
assay was performed at the Regional Center for Mycology &
Biotechnology (RCMP), Al-Azhar University using Doxoru-
bicin, Vinblastine and Colchicine as a reference cytotoxic com-
pound under different concentrations (50, 25, 12.5, 6.25, 3.125,
1.56 and 0 lg/ml). The results were expressed as growth inhibi-
tory concentration (IC50) values which represent the com-
pound concentrations required to produce a 50% inhibition
of cell growth after 24 h of incubation compared to untreated
controls as shown in Table 1 and Fig. 1. The results from
Table 1 explicated that some of the prepared compounds dis-played excellent to modest or fair growth inhibitory activity
against the tested cancer cell lines. Investigations of the cyto-
toxic activity against MCF-7 indicated that compounds 19,
7b, 12, 7a, 16, 2, 17, 1 (IC50 = 0.24–17.7 lg/ml, respectively)
were the most sensitive as compared to the three standards
drugs and the other new compounds. Compounds 19
(IC50 = 0.24 lg/ml) was found to be the most potent deriva-
tive overall the tested compounds against MCF-7 as it was
1.8 times more active than Doxorubicin (IC50 = 0.43 lg/ml),
while compounds 19, 7b, 12, 7a, 16 with (IC50 = 0.24–
6.0 lg/ml, respectively), were more efficacious than Vinblastine
(IC50 = 6.1 lg/ml) and compounds 19, 7b, 12, 7a, 16, 2, 17
(IC50 = 0.24–8.9 lg/ml, respectively) displayed good cytotoxi-
city compared to Colchicine (IC50 = 17.7 lg/ml), while com-
pound 1 was equipotent (IC50 = 17.7 lg/ml) as Colchicine.
Besides, compounds 19, 7b, 12, 16, 1, 2, 20, 14, 17, 8
(IC50 = 0.32–26.1 lg/ml, respectively) have a significant
potent antitumor activity against HCT-116 as compared to
The anti-proliferative activity of novel 4H-benzo[h]chromenes and 7H-benzo[h]-chromeno[2,3-d]pyrimidines 89the three standards drugs. Compounds 19 (IC50 = 0.32 lg/ml)
was found to be the most potent derivative overall the tested
compounds against HCT-116 as it was 1.5 times more active
than Doxorubicin (IC50 = 0.47 lg/ml), while compounds 19,
7b, 12 (IC50 = 0.32–1.0 lg/ml, respectively) were more potent
against HCT-116 as compared to Vinblastine (IC50 = 2.6 lg/
ml) and compounds 19, 7b, 12, 16, 1, 2, 20, 14, 17, 8
(IC50 = 0.32–26.1 lg/ml, respectively) were found to be the
most potent derivative against HCT-116 as compared to
Colchicine (IC50 = 42.8 lg/ml). On the other hand, cytotoxicity
evaluation in HepG-2 cell line revealed that compounds 7b,
17, 7a, 19, 1, 16, 18 (IC50 = 0.37–9.6 lg/ml, respectively) has
the higher activity as compared to the three standards. Com-
pound 7b was found to be the most potent derivative overall
the tested compounds against HepG-2 as it was 2.4 times more
active than Doxorubicin (IC50 = 0.9 lg/ml), while compounds
7b, 17, 7a (IC50 = 0.37–3.1 lg/ml, respectively) were more
potent against HepG-2 as compared to Vinblastine
(IC50 = 4.6 lg/ml) and compounds 7b, 17, 7a, 19, 1, 16, 18
(IC50 = 0.37–9.6 lg/ml, respectively) have a significant potent
activity against HepG-2 as compared to Colchicine
(IC50 = 10.6 lg/ml). And, the other compounds displayed
equipotent or moderate to lower cytotoxicity as compared to
Doxorubicin, Vinblastine and Colchicine.
3.3. SAR studies
The preliminary SAR study has focused on the effect of
replacement at the 2-, 3-, or 2, 3-positions, on the antitumor
activities of the synthesized compounds. In a comparison of
the cytotoxic activities of compounds 1, 2 and their analogs
against MCF-7, HCT-116 and HepG-2, we found that incor-
porating a pyrimidine nucleus at 2, 3-positions with hydropho-
bic group (‚NH-8, –NH2-9) for compound 19
(IC50 = 0.24 lg/ml) has caused a remarkable enhancement in
the antitumor activity against MCF-7 as compared to Doxoru-
bicin (IC50 = 0.43 lg/ml), while incorporating a pyrimidine
nucleus at 2, 3-positions with hydrophobic group (‚NH-8,
–NH2-9) or hydrophilic group (–C‚O-8) for compound 19,
16 (IC50 = 0.24 and 6.0 lg/ml, respectively) and introduction
of hydrophobic groups (–NAc2, –N‚CHNH2, –NHAc) at
2-position for compounds 7b, 12, 7a (IC50 = 0.7–5.1 lg/ml,
respectively) with the cyano group at 3-position represented
the most active derivatives against MCF-7 as compared to
Vinblastine (IC50 = 6.1 lg/ml). Besides, compounds 19, 7b,
12, 7a, 16, 2, 17, 1 (IC50 = 0.24–17.7 lg/ml, respectively) dis-
played efficacious cytotoxicity compared to Colchicine
(IC50 = 17.7 lg/ml), suggesting that the pyrimidine nucleus
at 2, 3-positions or 4H-benzo[h]chromene nucleus with
hydrophobic group at 8, 9- or 2-positions respectively, was
indispensable for the activities against breast adenocarcinoma.
In the case of HCT-116, investigation of SAR revealed that
compound 19 (IC50 = 0.32 lg/ml) was potent against HCT-
116 as compared to Doxorubicin (IC50 = 0.47 lg/ml), while
compound 19, 7b, 12 (IC50 = 0.0.32–1.0 lg/ml, respectively)
represented the most active derivatives against HCT-116 as
compared to Vinblastine (IC50 = 2.6 lg/ml). In addition, com-
pounds 19, 7b, 12, 16, 1, 2, 20, 14, 17, 8 (IC50 = 0.24–26.1 lg/
ml, respectively) displayed good cytotoxicity compared to Col-
chicine (IC50 = 42.8 lg/ml), suggesting that antitumor activity
is significantly affected by the presence of the pyrimidinenucleus at 2, 3-positions with hydrophobic group at 8, 9-
positions and the chromene nucleus with the hydrophobic
group at 2-position.
Further investigation of the impact of substitution pattern
at the 2- or 3-, 2, 3-positions on the prepared 4H-chromenes
and 7H-chromenopyrimidines activities against HepG-2 was
then conducted. Introduction of the hydrophobic group
(–NAc2) at 2-position for compounds 7b showed increased in
activity (IC50 = 0.37 lg/ml) against HepG-2 as compared to
Doxorubicin (IC50 = 0.9 lg/ml), while compounds 7b, 17, 7a
(IC50 = 0.37–3.1 lg/ml, respectively) were more potent against
HepG-2 as compared to Vinblastine (IC50 = 4.6 lg/ml) and
compounds 7b, 17, 7a–19, 1, 16, 18 (IC50 = 0.37–9.6 lg/ml,
respectively) have a significant potent activity against
HepG-2 as compared to Colchicine (IC50 = 10.6 lg/ml),
implying that introduction of the hydrophobic group (–NAc2)
at 2-position of the chromene nucleus and incorporating a
pyrimidine nucleus at 2, 3-positions with hydrophobic group
(–NH2) at 8-position was indispensable for the activities
against hepatocellular carcinoma.
Finally, we can deduce that the substitution pattern at the
2-, 3- or 2, 3-positions on the prepared 4H-chromene and
pyrimidine moiety is a crucial element for the antitumor activ-
ity. The incorporation of pyrimidine nucleus at 2, 3-positions
with hydrophobic group as (‚NH-8, –NH2-9) or (–NAc2,
–N‚CHNH2 –NHAc) at 2-position of the chromene nucleus
is favorable and greatly enhanced the activity than the other
hydrophobic and hydrophilic groups.
4. Conclusion
In summary, we have synthesized fifteen 4H-benzo[h]chromene
and 7H-benzo[h]chromeno[2,3-d]pyrimidine derivatives and
evaluated their cytotoxic activities against three cancer cell
lines (MCF-7, HCT-116 and HepG2). Most of the prepared
compounds displayed relatively potent and selective cytotoxic
activity against the three cancer cell lines. In particular, com-
pounds 19 (IC50 = 0.24 and 0.32 lg/ml, respectively) and 7b
(IC50 = 0.37 lg/ml) were 1.8, 1.5 and 2, 4 times, respectively
more active than Doxorubicin (IC50 = 0.43, 0.47 and 0.9 lg/
ml, respectively) against MCF-7, HCT-116 and HepG2 respec-
tively, while compounds 19, 7b, 12, 7a, 16 displayed the highest
activity against MCF-7 with IC50 values ranging from 0.24–
6.0 lg/ml, respectively than Vinblastine (IC50 = 6.1 lg/ml)
and Colchicine (IC50 = 17.7 lg/ml) and compounds 2, 17, 1
displayed good cytotoxicity with IC50 values ranging from
6.0–17.7 lg/ml, respectively compared to Colchicine
(IC50 = 17.7 lg/ml). Besides, compounds 19, 7b, 12 with
(IC50 = 0.32–1.0 lg/ml, respectively) were more potent against
HCT-116 as compared to Vinblastine (IC50 = 2.6 lg/ml) and
Colchicine (IC50 = 42.8 lg/ml), while compounds 16, 1, 2,
20, 14, 17, 8 (IC50 = 3.7–26.1 lg/ml, respectively) were found
to be the most potent derivatives against HCT-116 as com-
pared to Colchicine (IC50 = 42.8 lg/ml). Furthermore, com-
pounds 7b, 17, 7a with (IC50 = 0.37–3.1 lg/ml, respectively)
were more potent against HepG-2 as compared to Vinblastine
(IC50 = 4.6 lg/ml) and Colchicine (IC50 = 10.6 lg/ml), while
compounds 19, 1, 16, 18 (IC50 = 5.1–9.6 lg/ml, respectively)
have a significant potent activity against HepG-2 as compared
to Colchicine (IC50 = 10.6 lg/ml). And, the other compounds
displayed equipotent or moderate to lower cytotoxicity as
90 A.M. El-Agrody et al.compared to the three standards drugs. From the Structure
Activity Relationships (SARs), we can deduce that the incor-
poration of pyrimidine nucleus at 2, 3-positions with
hydrophobic group and hydrophobic group at 2-position of
the chromene nucleus is favorable and greatly enhanced the
activity than the other hydrophobic and hydrophilic groups.Acknowledgements
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